Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36129834)

  • 1. PARP in colorectal cancer: Molecular mechanisms, immunity, clinical trials, and drug combinations.
    Wu FH; Wei HZ; Deng HY; Xiao GH; Zhang YC
    Neoplasma; 2023 Feb; 70(1):1-14. PubMed ID: 36129834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function.
    Li J; Li Q; Zhang L; Zhang S; Dai Y
    Biomed Pharmacother; 2023 Jan; 157():114028. PubMed ID: 36410122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
    Padella A; Ghelli Luserna Di RorĂ  A; Marconi G; Ghetti M; Martinelli G; Simonetti G
    J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly(ADP-Ribose) Polymerase Inhibition Sensitizes Colorectal Cancer-Initiating Cells to Chemotherapy.
    Jarrar A; Lotti F; DeVecchio J; Ferrandon S; Gantt G; Mace A; Karagkounis G; Orloff M; Venere M; Hitomi M; Lathia J; Rich JN; Kalady MF
    Stem Cells; 2019 Jan; 37(1):42-53. PubMed ID: 30353615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP mediated DNA damage response, genomic stability and immune responses.
    Zong C; Zhu T; He J; Huang R; Jia R; Shen J
    Int J Cancer; 2022 Jun; 150(11):1745-1759. PubMed ID: 34952967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
    Rabenau K; Hofstatter E
    Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual antitumor immunomodulatory effects of PARP inhibitor on the tumor microenvironment: A counterbalance between anti-tumor and pro-tumor.
    Yi XF; Gao RL; Sun L; Wu ZX; Zhang SL; Huang LT; Han CB; Ma JT
    Biomed Pharmacother; 2023 Jul; 163():114770. PubMed ID: 37105074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
    Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A
    Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942
    [No Abstract]   [Full Text] [Related]  

  • 9. MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers.
    Vilar E; Bartnik CM; Stenzel SL; Raskin L; Ahn J; Moreno V; Mukherjee B; Iniesta MD; Morgan MA; Rennert G; Gruber SB
    Cancer Res; 2011 Apr; 71(7):2632-42. PubMed ID: 21300766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
    Lau CH; Seow KM; Chen KH
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP and PARG inhibitors in cancer treatment.
    Slade D
    Genes Dev; 2020 Mar; 34(5-6):360-394. PubMed ID: 32029455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Research progress on the association between environmental pollutants and the resistance mechanism of PARP inhibitors in ovarian cancer.
    Zhou L; Xiang J; He Y
    Environ Sci Pollut Res Int; 2021 Sep; 28(36):49491-49506. PubMed ID: 34370190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolving DNA repair synthetic lethality targets in cancer.
    Kulkarni S; Brownlie J; Jeyapalan JN; Mongan NP; Rakha EA; Madhusudan S
    Biosci Rep; 2022 Dec; 42(12):. PubMed ID: 36420962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unravelling the Role of PARP1 in Homeostasis and Tumorigenesis: Implications for Anti-Cancer Therapies and Overcoming Resistance.
    Lovsund T; Mashayekhi F; Fitieh A; Stafford J; Ismail IH
    Cells; 2023 Jul; 12(14):. PubMed ID: 37508568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells.
    Ito S; Murphy CG; Doubrovina E; Jasin M; Moynahan ME
    PLoS One; 2016; 11(7):e0159341. PubMed ID: 27428646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
    Dulaney C; Marcrom S; Stanley J; Yang ES
    Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP inhibitor resistance: the underlying mechanisms and clinical implications.
    Li H; Liu ZY; Wu N; Chen YC; Cheng Q; Wang J
    Mol Cancer; 2020 Jun; 19(1):107. PubMed ID: 32563252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly adenosine diphosphate-ribosylation, a promising target for colorectal cancer treatment.
    Jeong KY; Park M
    World J Gastrointest Oncol; 2021 Jun; 13(6):574-588. PubMed ID: 34163574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review.
    Mehta P; Bothra SJ
    Adv Genet; 2021; 108():35-80. PubMed ID: 34844716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?
    Duma N; Gast KC; Choong GM; Leon-Ferre RA; O'Sullivan CC
    Curr Oncol Rep; 2018 Jun; 20(8):63. PubMed ID: 29884921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.